PFM Health Sciences

Outset Medical, Inc. is a medical technology company based in San Jose, California, focused on innovating dialysis solutions for patients and healthcare providers. The company has developed the Tablo system, a hemodialysis machine designed for both acute and chronic care settings. Tablo features a compact console with integrated water purification, on-demand dialysate production, and advanced connectivity capabilities, including wireless data and sensor-based automation. This design aims to simplify the complexities and costs associated with dialysis, making it suitable for use in hospitals, dialysis clinics, and home settings. Originally founded as Home Dialysis Plus, Ltd. in 2003, the company rebranded to Outset Medical, Inc. in January 2015.

Mendaera is a medtech startup dedicated to advancing healthcare technologies, particularly through the development of surgical robots and diagnostic tools. The company aims to digitize clinical judgment and technical expertise, ensuring that high-quality care is accessible to all patients in various care settings. Mendaera's platform, currently under development, integrates robotics, artificial intelligence, real-time imaging, and connectivity to facilitate precise and consistent point-of-care interventions. By aiding physicians in image acquisition and interpretation, Mendaera seeks to eliminate barriers in the patient journey, accelerate recovery, and reduce healthcare costs, thereby enhancing the capabilities of healthcare professionals in performing medical procedures effectively.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

Tenaya Therapeutics is a preclinical stage biotechnology company based in South San Francisco, California, specializing in the development of innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs a multipronged approach to address the fundamental cellular pathologies associated with cardiac muscle disease. Tenaya Therapeutics advances its product candidates through three primary platforms: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads to cardiac fibroblasts, and a precision medicine platform that offers personalized treatment strategies. Through its research, the company aims to enable physicians to regenerate heart tissue and tackle various forms of cardiomyopathies effectively.

COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.

Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Apella is an AI startup focused on enhancing surgical practices through advanced healthcare technology. Founded in 2019 and based in San Francisco, California, the company utilizes artificial intelligence and computer vision to collect and analyze data from operating rooms. By digitizing the surgical environment, Apella aims to improve operational efficiency, surgical quality, and training, while also facilitating real-time decision-making for surgeons and medical staff. Its innovative approach seeks to generate new insights that contribute to better outcomes in surgical procedures.

Lark is a developer of a virtual platform focused on chronic disease prevention and management. Founded in 2011 by Julia Hu and Jeff Zira, the company is headquartered in Mountain View, California. Lark's platform leverages advanced artificial intelligence alongside human coaching and connected devices to offer real-time, personalized support and counseling. This approach aims to help users make healthier choices and effectively manage their chronic conditions. The company's programs, including those recognized by the CDC for diabetes prevention, wellness, diabetes care, and hypertension, serve approximately 1.5 million users. These initiatives have shown clinically validated improvements in health outcomes, as documented in multiple peer-reviewed journals and analyst reports.

Caresyntax Inc. is a Boston-based company that provides a digital surgery platform to enhance surgical performance in hospitals and ambulatory surgical centers. Founded in 1991, it leverages data from over 1,600 hospitals globally to deliver insights that improve patient outcomes and operational efficiency. The platform integrates various data sources, including video, audio, clinical, and operational data, enabling real-time analysis and decision-making during surgeries. Caresyntax offers solutions such as qvident, a performance management software, and PRIME365, a comprehensive integration platform that consolidates surgical data and content. With a focus on automating workflows and reducing surgical variability, Caresyntax supports over 4,000 operating rooms and has facilitated millions of surgical procedures worldwide. The company’s HIPAA-compliant software can be deployed on-premise, in the cloud, or in a hybrid format, making it adaptable to diverse healthcare environments.

Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

CMR Surgical, established in 2014 and headquartered in Cambridge, UK, specializes in designing and manufacturing medical devices for minimal access surgery. The company's primary product is the Versius surgical robotic system, which facilitates laparoscopic surgery by providing surgeons with 3D high-definition imagery and feedback. CMR Surgical aims to make minimal access surgery universally accessible and affordable by expanding the range of procedures that can be performed using its robotic systems.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and headquartered in Wilmington, Delaware. The company specializes in the discovery and development of small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. Utilizing a discovery approach informed by target structure biology, NiKang employs structure-based drug design to facilitate the rapid and efficient development of proprietary drug candidates. This methodology enables the company to create innovative therapies with desirable pharmacological properties, ultimately aimed at improving the lives of patients through enhanced treatment options.

Collective Health is a health benefits platform that integrates various medical, dental, vision, and pharmacy services into a cohesive solution aimed at simplifying healthcare for employees and their families. The company’s cloud-based platform streamlines the administration of health plans through a single portal, offering clear guidance, live concierge support, and digital tools for managing care. By reducing the administrative burden associated with health benefits, Collective Health enhances the member experience and aids organizations in controlling costs while improving health outcomes. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.

Boundless Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, focused on developing innovative therapies for the treatment of aggressive cancers. The company specializes in targeting extrachromosomal DNA (ecDNA), a key factor in the amplification of oncogenes that affects over 14% of cancer patients. By investigating the biology of ecDNA, Boundless Bio aims to create transformative treatments for previously untreatable cancers. Its lead therapeutic candidate, BBI-355, is an oral selective inhibitor of checkpoint kinase 1 (CHK1) designed to manage the replication and transcription of ecDNA in cancer cells. Founded in 2018, Boundless Bio is committed to addressing the significant unmet medical needs of patients with oncogene amplified tumors.

Crossover Health, established in 2010, specializes in providing comprehensive workplace healthcare services for employers and their employees. Headquartered in Aliso Viejo, California, with health centers across the United States, the company offers a wide range of services including primary care, urgent care, chronic disease management, health coaching, physical therapy, and more. Crossover Health aims to deliver exceptional member experiences and advanced health management services, ultimately promoting a healthy and motivated workforce for its clients.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California, that specializes in developing innovative therapeutics for oncology and infectious diseases, with a particular emphasis on targeting dysfunctional lipid metabolism pathways. The company has a strong focus on fatty acid synthase (FASN) biology and has developed a pipeline of proprietary FASN inhibitors. Its lead product candidate, denifanstat, is an oral selective FASN inhibitor being investigated for the treatment of nonalcoholic steatohepatitis (NASH). Additionally, Sagimet is exploring antiviral therapeutic candidates aimed at treating respiratory syncytial virus, cytomegalovirus, and other human pathogens. Founded in 2006, Sagimet Biosciences was previously known as 3-V Biosciences, Inc. before rebranding in August 2019.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its unique T-win technology platform, the company creates first-in-class immune-modulating cancer vaccines that aim to activate T cells specific to immune-suppressive molecules. This approach allows for the simultaneous targeting and disruption of multiple pathways that tumors exploit to evade the immune response. IO Biotech has demonstrated a strong capability in advancing its preclinical and clinical candidates, with its two leading compounds targeting IDO and PD-L1 currently in clinical development, while several others are in the preclinical phase.

Cytrellis Biosystems, Inc. is a clinical stage medical technology company focused on designing and developing innovative devices for dermatology, scar reduction, and aesthetic medicine. Founded in 2011 and headquartered in Sherborn, Massachusetts, the company aims to address age-related skin changes through non-surgical solutions. Its products are specifically engineered to remove sagging skin without the need for invasive procedures or scarring, thereby offering aesthetic practitioners enhanced capabilities to improve the appearance of aging skin. Cytrellis Biosystems is dedicated to advancing the field of aesthetic medicine with its cutting-edge technologies.